You are here

Article Text

Article menu
Download PDFPDF
Letter
CTLA-4 CT60 polymorphism is not an independent genetic risk marker of rheumatoid arthritis in a Japanese population
  1. S Tsukahara,
  2. T Iwamoto,
  3. K Ikari,
  4. E Inoue,
  5. T Tomatsu,
  6. M Hara,
  7. H Yamanaka,
  8. N Kamatani,
  9. S Momohara
  1. Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
  1. Katsunori Ikari, MD, PhD, Institute of Rheumatology, Tokyo Women’s Medical University, 10–22 Kawada, Shinjuku, Tokyo 162-0054, Japan; kikari{at}ior.twmu.ac.jp

https://doi.org/10.1136/ard.2007.079186

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) molecule belongs to the immunoglobulin superfamily and is a critical down-regulatory molecule expressed on T cells that inhibits T cell activation and maintains peripheral tolerance.1 Previous meta-analyses indicated that exon 1 +49G (rs231775) on CTLA-4 could be a possible genetic risk factor for rheumatoid arthritis (RA).2 3 It causes a non-synonymous substitution in the CTLA-4 protein and has been suggested to influence inhibitory function of CTLA-4 by changing the cell surface expression.4 Recently, CT60 (rs3087243), another polymorphism on 3′ untranslated region, was identified as a disease causal variant for a variety of autoimmune diseases.5 The result was confirmed in a large-scale population of European descent with RA and in a Han Chinese population with RA. …

    View Full Text

    Footnotes

    • Funding: This work was supported by a grant provided by the Japan Orthopaedics and Traumatology Foundation (to K.I.), Takeda Science Foundation (to K.I.) and a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology (to K.I. and S.T.). We are also grateful to 36 pharmaceutical companies for the support of the IORRA study, and Professor Taniguchi and other members of our institute for their efforts on the IORRA cohort.

    • ST and TI contributed equally to this work.

    • Competing interests: None.